Heart Failure Treatment Options: From Medication to Heart Transplant

Heart failure affects an estimated 64 million people worldwide. It is one of the leading causes of hospitalisation in adults over 65, responsible for enormous personal suffering and healthcare expenditure across every region of the world. Yet the past five years have seen more meaningful advances in heart failure treatment than the previous two decades combined.

The key shift is that heart failure is no longer treated as a single condition. It is now managed as a spectrum, with treatment decisions calibrated to the degree of heart pump function reduction: mildly reduced or preserved. That distinction drives everything from medication choice to device eligibility to how aggressively therapy is escalated after a first hospitalisation.

For patients newly diagnosed with heart failure and those managing it long-term, understanding the full range of available options, what each does, and when it applies is the starting point for making informed decisions alongside a cardiologist.

Heart Failure Treatment Options at a Glance

• Medications (GDMT)
• CRT and ICD devices
• SGLT2 inhibitors
• LVAD support
• Heart transplant
• Lifestyle management

What Is Heart Failure and How Is It Classified?

Heart failure does not mean the heart has stopped. It means the heart can no longer pump enough blood to meet the body's demands, or can only do so at abnormally high filling pressures.

Cardiologists classify heart failure by left ventricular ejection fraction (LVEF), the percentage of blood the heart ejects with each beat:

• HFrEF (Heart Failure with Reduced Ejection Fraction): LVEF below 40 percent. The heart muscle is weakened and pumps less efficiently. This is the most studied form, and the one with the largest evidence base for treatment.
• HFmrEF (Mildly Reduced Ejection Fraction): LVEF 41 to 49 percent. A middle zone increasingly recognised as a distinct clinical phenotype with its own treatment implications.
• HFpEF (Preserved Ejection Fraction): LVEF 50 percent or above. The heart muscle is stiff rather than weak, impairing filling rather than pumping. HFpEF now accounts for more than half of all heart failure cases and, until recently, had far fewer evidence-based treatment options.

Common Causes

Heart failure develops from underlying conditions that either weaken or stiffen the heart muscle. The most frequent causes include:

• Coronary artery disease and previous myocardial infarction
• Longstanding uncontrolled hypertension
• Cardiomyopathy (genetic or acquired)
• Valve disease
• Diabetes and obesity, particularly in HFpEF
• Atrial fibrillation causing tachycardia-mediated cardiomyopathy

What Are the Four Pillars of Heart Failure Treatment?

For patients with HFrEF, current evidence supports four classes of medication that together form guideline-directed medical therapy (GDMT). Used together, these four drug classes reduce mortality, hospitalisation rates, and progression of disease more effectively than any individual agent alone.

Beta-Blockers

Beta-blockers, including carvedilol, bisoprolol, and metoprolol succinate, slow the heart rate, reduce neurohormonal activation that drives disease progression, and allow the weakened heart muscle to recover over time. They form the cornerstone of HFrEF therapy and are initiated in all stable patients regardless of symptom severity.

ACE Inhibitors, ARBs, and ARNIs

Renin-angiotensin system blockade with ACE inhibitors or angiotensin receptor blockers has been standard since the 1980s. Sacubitril-valsartan (brand name Entresto), an angiotensin receptor-neprilysin inhibitor (ARNI), has superseded ACE inhibitors as the preferred agent in most HFrEF patients who tolerate it. Data show sacubitril-valsartan reduces the risk of cardiovascular death or heart failure hospitalisation by 20 percent compared to enalapril.

Mineralocorticoid Receptor Antagonists (MRAs)

Spironolactone and eplerenone block the effects of aldosterone on the heart and kidneys, reducing fluid retention and myocardial fibrosis. Both reduce mortality in HFrEF. Finerenone, a newer nonsteroidal MRA, received FDA approval in July 2025 specifically for HFpEF and HFmrEF, marking the first approval of this drug class across the spectrum of preserved ejection fraction.

SGLT2 Inhibitors

Dapagliflozin and empagliflozin were originally developed for type 2 diabetes but are now recommended across the full ejection fraction spectrum in heart failure. SGLT2 inhibitors reduce heart failure hospitalisations, slow the decline in kidney function, and improve quality of life. They work through mechanisms largely independent of glycaemic control, making them beneficial in patients with and without diabetes.

Best Treatment Options for HFpEF (Heart Failure with Preserved Ejection Fraction)

For years, HFpEF was the form of heart failure where medicine largely ran out of options after diuretics for symptom relief. That has changed significantly.

Treatments Now Supported for HFpEF

• SGLT2 inhibitors: Now recommended across the full EF spectrum based on trial evidence showing reduced hospitalisations in HFpEF
• Finerenone (Kerendia): FDA-approved in July 2025 for HFpEF and HFmrEF, based on the FINEARTS-HF trial showing meaningful reductions in heart failure events
• Semaglutide (Ozempic/Wegovy) for obese patients with HFpEF: trial data from STEP-HFpEF showed significant improvement in quality of life, exercise capacity, and weight reduction over 52 weeks in obese HFpEF patients

The Fifth Drug for Worsening HF

Vericiguat, a soluble guanylate cyclase stimulator, is now available for patients who experience worsening heart failure despite maximum tolerated GDMT. It targets a different molecular pathway from the four pillars and provides additional benefit in patients at the highest risk of hospitalisation.

What Device Therapies Are Available For Heart Failure Treatment?

When medication alone cannot adequately control heart failure, device-based therapies offer additional mechanical or electrical support.

Cardiac Resynchronisation Therapy (CRT)

In patients with HFrEF and a prolonged QRS duration on ECG (typically 130-150 milliseconds), the left and right ventricles lose their coordinated contraction sequence. CRT uses a specialised pacemaker to resynchronise ventricular contraction. 

Data consistently show CRT improves ejection fraction, reduces symptoms, and decreases mortality in appropriately selected patients. Many patients achieve a meaningful rise in ejection fraction following CRT, a phenomenon known as reverse remodelling.

Implantable Cardioverter Defibrillator (ICD)

Patients with HFrEF (LVEF below 35 percent) and moderate-to-severe symptoms carry a significantly elevated risk of sudden cardiac death from ventricular arrhythmia. An ICD continuously monitors heart rhythm and delivers an electric shock to restore normal rhythm if a life-threatening arrhythmia occurs. It does not treat heart failure directly, but it reduces the risk of sudden death in high-risk patients.

CardioMEMS and Remote Haemodynamic Monitoring

The CardioMEMS HF System implants a wireless sensor in the pulmonary artery via catheter. The sensor measures pulmonary artery pressure daily and transmits data to the treating cardiologist. Elevated pressures signal worsening congestion before symptoms become apparent, allowing medication adjustments to prevent hospitalisation. This haemodynamic-guided management approach reduces heart failure hospitalisations significantly in both HFrEF and HFpEF populations.

As Dr. Ashok Seth, Chairman of Fortis Escorts Heart Institute in New Delhi, has noted: "Managing heart failure reactively, waiting for the patient to deteriorate and present in crisis, is an outdated model. The technology now exists to detect worsening congestion days before the patient feels it. Centres that integrate this into routine practice see fewer emergency admissions."

When Is a Left Ventricular Assist Device (LVAD) Considered?

An LVAD is a mechanical pump surgically implanted to support or replace the function of a severely failing left ventricle. Blood flows into the device from the left ventricle and is pumped out into the aorta, bypassing the weakened heart muscle.

Clinical Indications

• Bridge to transplantation: An LVAD is implanted to keep a critically ill patient alive and functional while awaiting a donor heart.
• Destination therapy: For patients who are not heart transplant candidates, an LVAD is implanted as a permanent treatment. Data from the MOMENTUM 3 trial, using the HeartMate 3 centrifugal-flow device, showed that 79.5 percent of patients were free of disabling stroke or reoperation at 2 years, establishing LVAD as a durable long-term option for advanced heart failure.

Modern LVADs such as the HeartMate 3 and HVAD use continuous-flow centrifugal pump technology that is significantly more reliable and associated with fewer adverse events than earlier axial-flow devices.

What Is Heart Transplantation and Who Qualifies?

Heart transplantation remains the definitive treatment for end-stage heart failure refractory to all other therapies. Survival data show one-year survival rates above 85 percent and ten-year survival of approximately 55 percent after transplantation.

Eligibility Criteria

Candidates typically meet the following profile:

• Advanced heart failure (NYHA Class III to IV) despite maximum GDMT and device therapy
• No response to LVAD or not suitable for LVAD
• No contraindications including significant kidney disease, active infection, malignancy, severe pulmonary hypertension, or age above 65 in most programmes
• Good psychosocial support and demonstrated medication adherence

Donor heart availability is the primary limiting factor globally. Waiting times range from months to years depending on blood type, body size, and recipient urgency status. This wait period is why LVAD as a bridge to transplantation is critical for patients who would not survive the wait without mechanical circulatory support.

Lifestyle, Monitoring, and Self-Management

Medical and device therapy cannot carry the full burden of heart failure management alone. Evidence is consistent that lifestyle modifications and daily monitoring meaningfully reduce hospitalisation rates and slow disease progression.

• Daily weight monitoring: A gain of more than one to two kilograms over two to three days signals fluid accumulation that warrants medication adjustment before symptoms escalate
• Sodium restriction to below 2,000 to 2,500 mg per day reduces fluid retention and lowers the diuretic dose needed
• Fluid restriction to one to two litres daily in patients with advanced HF reduces congestion risk
• Supervised exercise rehabilitation: Data from multiple trials shows cardiac rehabilitation improves exercise capacity, quality of life, and reduces hospitalisation rates in stable HFrEF
• Medication adherence: Stopping any of the four GDMT pillars abruptly significantly increases the risk of acute decompensation

How to Access Heart Failure Treatment in India?

Patients from regions where advanced heart failure therapies are unavailable, where device implantation waiting lists are long, or where LVAD and transplantation programmes do not exist at all, increasingly travel to India and other medical destinations for treatment.

What India Offers

India's leading cardiac centres offer the full spectrum of heart failure management:

• Initiation and optimisation of GDMT including sacubitril-valsartan and SGLT2 inhibitors
• CRT and ICD implantation with electrophysiology programmes
• CardioMEMS implantation for remote haemodynamic monitoring
• LVAD surgery (HeartMate 3 and similar devices) as bridge to transplant or destination therapy
• Heart transplantation at selected high-volume cardiac centres

Costs for device-based therapies in India are 50 to 75 percent lower than those for equivalent procedures in Western Europe and the United States. 

CRT device implantation costs approximately USD 8,000 to USD 15,000 in India, including the device, compared to USD 40,000 to USD 80,000 in the United States. 

LVAD implantation in India costs approximately USD 40,000 to USD 60,000 compared to USD 150,000 to USD 300,000 in the United States, with the device cost accounting for the majority of the difference.

Conclusion

The narrative around heart failure has changed fundamentally in the past decade. A diagnosis that once carried the expectation of steady decline is now manageable for years or decades with appropriate therapy, and the available tools have expanded significantly with each passing year.

The GDMT revolution in HFrEF has been followed by meaningful advances in HFpEF, closing a gap that left millions of patients with limited options. Device therapy has moved from an adjunct to a central pillar of advanced heart failure management. And for patients reaching the end of the medical and device road, LVAD and transplantation offer options that were not accessible to most patients a generation ago.

The patients who do best are those who access the full range of treatment early, understand the role of each intervention, and maintain the daily discipline that medication and devices alone cannot substitute for.

Disclaimer: This article provides general information about heart failure treatment options. It does not constitute medical advice and must not replace a consultation with a qualified cardiologist or cardiac specialist. Individual treatment decisions depend on heart failure classification, ejection fraction, symptom severity, comorbidities, and patient-specific factors. Patients should consult their treating cardiologist before making any changes to treatment.